These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31811290)

  • 1. Hepatitis C virus infection and the role of a pharmaceutical care program.
    Chamorro-de-Vega E; Rodríguez-González CG; Giménez-Manzorro Á; Herranz A; Sanjurjo M
    Am J Health Syst Pharm; 2020 Mar; 77(6):479-486. PubMed ID: 31811290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project.
    Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Gimenez-Manzorro A; de Lorenzo-Pinto A; Iglesias-Peinado I; Herranz A; Sanjurjo M;
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28836363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
    Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Heredia Benito M; García-Cabrera E; Monje García B; Tovar Pozo M; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Apr; 41(2):488-495. PubMed ID: 31028599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program.
    Ajlan AA; Al-Gain R; Ahmed M; Abu-Riash T; Alquaiz M; Alkhail FA; Alashgar H; Alkhairallah T; Alkortas D; Al-Jedai A
    J Am Pharm Assoc (2003); 2021; 61(2):e159-e170. PubMed ID: 33309191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacy programmatic perspectives on use of direct-acting antivirals for acquired hepatitis C infection in solid organ transplant recipients.
    Crona L; Berry H; Byrns J; Campbell U
    Am J Health Syst Pharm; 2020 Jul; 77(14):1149-1152. PubMed ID: 32537658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy.
    Kuo MH; Tseng CW; Lee CH; Yang YC; Wu HJ; Lin HJ; Chu YL; Chen YC; Tseng KC
    J Formos Med Assoc; 2022 Jan; 121(1 Pt 1):58-65. PubMed ID: 33518448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy.
    Mohammad RA; Bulloch MN; Chan J; Deming P; Love B; Smith L; Dong BJ; GI Liver Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy
    Pharmacotherapy; 2014 Dec; 34(12):1341-54. PubMed ID: 25359244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
    Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
    Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication therapy management: 10 years of experience in a large integrated health care system.
    Ramalho de Oliveira D; Brummel AR; Miller DB
    J Manag Care Pharm; 2010 Apr; 16(3):185-95. PubMed ID: 20331323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
    Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
    Langness JA; Nguyen M; Wieland A; Everson GT; Kiser JJ
    World J Gastroenterol; 2017 Mar; 23(9):1618-1626. PubMed ID: 28321163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction.
    Ribed A; Romero-Jiménez RM; Escudero-Vilaplana V; Iglesias-Peinado I; Herranz-Alonso A; Codina C; Sanjurjo-Sáez M
    Int J Clin Pharm; 2016 Apr; 38(2):280-8. PubMed ID: 26715547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
    Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
    J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
    AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype 1 hepatitis C virus and the pharmacist's role in treatment.
    Sebhatu P; Martin MT
    Am J Health Syst Pharm; 2016 Jun; 73(11):764-74. PubMed ID: 27126832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management.
    Brummel A; Lustig A; Westrich K; Evans MA; Plank GS; Penso J; Dubois RW
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1152-8. PubMed ID: 25597053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.